Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Neurology, A.C.O. San Filippo Neri, Rome, Italy.
J Neural Transm (Vienna). 2021 Mar;128(3):321-335. doi: 10.1007/s00702-021-02312-4. Epub 2021 Feb 26.
Botulinum toxin (BT) therapy is a complex and highly individualised therapy defined by treatment algorithms and injection schemes describing its target muscles and their dosing. Various consensus guidelines have tried to standardise and to improve BT therapy. We wanted to update and improve consensus guidelines by: (1) Acknowledging recent advances of treatment algorithms. (2) Basing dosing tables on statistical analyses of real-life treatment data of 1831 BT injections in 36 different target muscles in 420 dystonia patients and 1593 BT injections in 31 different target muscles in 240 spasticity patients. (3) Providing more detailed dosing data including typical doses, dose variabilities, and dosing limits. (4) Including total doses and target muscle selections for typical clinical entities thus adapting dosing to different aetiologies and pathophysiologies. (5) In addition, providing a brief and concise review of the clinical entity treated together with general principles of its BT therapy. For this, we collaborated with IAB-Interdisciplinary Working Group for Movement Disorders which invited an international panel of experts for the support.
肉毒毒素(BT)治疗是一种复杂且高度个体化的治疗方法,由治疗算法和注射方案定义,描述其目标肌肉及其剂量。各种共识指南都试图标准化和改进 BT 治疗。我们希望通过以下方式更新和改进共识指南:(1)承认治疗算法的最新进展。(2)根据对 420 例肌张力障碍患者的 36 个不同目标肌肉中的 1831 次 BT 注射和 240 例痉挛患者的 31 个不同目标肌肉中的 1593 次 BT 注射的真实治疗数据进行统计学分析,为剂量表提供依据。(3)提供更详细的剂量数据,包括典型剂量、剂量变化和剂量限制。(4)纳入典型临床实体的总剂量和目标肌肉选择,从而根据不同病因和病理生理学调整剂量。(5)此外,还提供了所治疗临床实体的简要概述以及其 BT 治疗的一般原则。为此,我们与运动障碍的跨学科工作组(IAB)合作,邀请了一个国际专家小组提供支持。